Revive Therapeutics Appoints Tessio Rebello, Ph.D. as Clinical Advisor

TORONTO, ONTARIO--(Marketwired - April 19, 2016) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett Syndrome, today announced that Tessio Rebello, Ph.D., will join the Company as a clinical advisor for the Company.

Dr. Rebello previously held the position of Vice President of Clinical Development at VIRxSYS Corporation where he led the successful launch of a first-in-class anti-sense, gene therapy (VRX496), Phase 2 clinical trial for the treatment of HIV-infected patients who fail to respond to conventional drug therapies and two other Phase 2 clinical trials involving the same drug. Prior to that, Dr. Rebello held the position of Director of Clinical Development at United Therapeutics Corporation and was Head of Cardiovascular Division and International Clinical Development at Sigma-tau Pharmaceuticals, Inc. Dr. Rebello has extensive experience in setting up Clinical Trials (from IND stage to Phase 3/4 Trials) and also experience interacting with the U.S. FDA, Principal Investigators and Contract Research Organizations. Dr. Rebello also led successful clinical trials in the treatment of chronic renal failure and peripheral arterial disease, which led to new drug approvals. Dr. Rebello earned his BSc (Honors) at the University of Liverpool and his Ph.D. at Guys Hospital Medical School at University of London, England.

"I am pleased that Dr. Rebello has joined Revive to assist with advancing the clinical developments of our product pipeline," said Fabio Chianelli, Chief Executive Officer of Revive. "Dr. Rebello has tremendous experience advancing new drugs through all clinical development phases towards drug approvals in the U.S. Dr. Rebello will be instrumental in navigating the clinical development of Bucillamine for the treatments of gout and rare diseases such as Cystinuria and Wilson's disease."

"I am very excited to be a part of the Revive team as we work to progress the Company's clinical development programs," said Dr. Rebello. "Treatments for gout and Cystinuria have shown to have limitations and I believe Bucillamine offers the opportunity to fill this unmet need as a potential effective therapy for these indications."

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. (TSX VENTURE:RVV)(OTCQB:RVVTF) is focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome. Additional information on Revive is available at www.ReviveThera.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward looking statements", which are not comprised of historical facts. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward looking statements in this news release include, without limitation, statements regarding: the granting of a patent for REV-002; the potential efficacy and commercial viability of REV-002 for treatment of gout and Bucillamine for the treatment of cystinuria; expansion of the REV-002 clinical testing program; the Company's drug research and development plans; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive, that clinical testing results will justify commercialization of the Company's drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates, that such approvals will be received on a timely basis, and that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms.
Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect. Factors that may cause actual results to differ materially from those anticipated by these forward looking statements include: uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Annual Information Form for the period ended June 30, 2014 and Revive's other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.